Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
NCT02450136
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
2
Enrollment
OTHER
Sponsor class
Conditions
Refractory Solid Tumors
Interventions
DRUG:
pazopanib
Sponsor
Samsung Medical Center